Zelavespib

N/A

Report date: 2023/04/03 12:33:05
NME

Base Information

Drug NameZelavespib
Drug Alias NamePU-H71
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP90 inhibitors
TargetsHeat shock protein HSP90
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursPrimary Myelofibrosis +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesSamus Therapeutics IncNational Cancer Institute
Active IndicationsMetastatic breast cancerSolid tumoursMyeloproliferative Disorders +[4] 
Inactive IndicationsPrimary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera

Other Information

ATC CodeN/A
Related LinksN/A